Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia
July 02, 2023 20:23 ET
|
Sosei Group Corporation
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated...
Sosei Heptares Provides Update on Lotiglipron Development
June 26, 2023 18:40 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 27 June 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1...
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
May 12, 2023 02:30 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter...
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting
March 23, 2023 03:00 ET
|
Sosei Group Corporation
Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb, elected to the Company’s Board of DirectorsCandelle Chong promoted to Executive Vice President and Chief of Staff,...
Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
March 14, 2023 20:05 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and...
Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
March 08, 2023 03:00 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and...
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022
February 14, 2023 01:30 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD)...
Sosei Heptares Webinar Presentation for FY2022 Financial Results
January 25, 2023 01:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused...
Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
January 05, 2023 02:37 ET
|
Sosei Group Corporation
TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by Sosei Heptares and out-licensed to Tempero BioPhase 1...
Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
December 20, 2022 19:01 ET
|
Sosei Group Corporation
PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10...